How Residual DNA Testing Is Becoming Essential to Advancing Biopharmaceutical Development
The residual DNA testing market is undergoing significant growth, driven by rising regulatory approvals for biologics and biosimilars, along with increased global investments in research and development. As of 2024, the market is heavily shaped by regulatory mandates that require manufacturers to demonstrate the safety, purity, and efficacy of biopharmaceutical products. For executives across pharmaceuticals,...